Model-Based Methods to Translate Adolescent Medicine Trials Network for HIV/AIDS Interventions Findings Into Policy Recommendations: Rationale and Protocol for a Modeling Core (ATN 161)
暂无分享,去创建一个
M. Hudgens | J. Parsons | K. Freedberg | I. Bassett | B. Stanton | Xiaoming Li | K. Simpson | C. Crespi | K. Simpson | A. Ciaranello | K. Horvath | S. Nachman | H. J. Rendina | K. Patel | K. Powers | A. Gaur | L. Hightow-Weidman | S. Naar | A. Agwu | K. Horvath | K. Amico | Audrey C Bangs | Anne M. Neilan
[1] Sung-Jae Lee,et al. Barriers and Facilitators to the Collection and Aggregation of Electronic Health Record HIV Data: An Analysis of Study Recruitment Venues Within the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) , 2021, Evaluation & the health professions.
[2] R. Bolan,et al. Acute HIV Infection in Youth: Protocol for the Adolescent Trials Network 147 (ATN147) Comprehensive Adolescent Research and Engagement Studies (CARES) Study , 2019, JMIR research protocols.
[3] S. Goodreau,et al. Potential Impact of HIV Preexposure Prophylaxis Among Black and White Adolescent Sexual Minority Males , 2018, American journal of public health.
[4] Travis Sanchez,et al. University of North Carolina/Emory Center for Innovative Technology (iTech) for Addressing the HIV Epidemic Among Adolescents and Young Adults in the United States: Protocol and Rationale for Center Development , 2018, JMIR research protocols.
[5] Вестник КемГУ. Network , 2018, Definitions.
[6] A. Sohn,et al. Simulation Modeling and Metamodeling to Inform National and International HIV Policies for Children and Adolescents , 2018, Journal of acquired immune deficiency syndromes.
[7] Matthew A Psioda,et al. Adolescent Medicine Trials Network for HIV/AIDS Interventions Data Harmonization: Rationale and Development of Guidelines , 2018, JMIR research protocols.
[8] J. Parsons,et al. Adolescent Trials Network for HIV-AIDS Scale It Up Program: Protocol for a Rational and Overview , 2018, JMIR research protocols.
[9] J. Sleasman,et al. Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy. , 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[10] J. Bauermeister,et al. Interaction Effects of Neighborhood Disadvantage and Individual Social Support on Frequency of Alcohol Use in Youth Living with HIV , 2018, American journal of community psychology.
[11] S. Goodreau,et al. Targeting Human Immunodeficiency Virus Pre-Exposure Prophylaxis to Adolescent Sexual Minority Males in Higher Prevalence Areas of the United States: A Modeling Study. , 2017, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[12] L. Myer,et al. Impact of Birth HIV-PCR Testing on the Uptake of Follow-up Early Infant Diagnosis Services in Cape Town, South Africa , 2017, The Pediatric infectious disease journal.
[13] R. Walensky,et al. The value of confirmatory testing in early infant HIV diagnosis programmes in South Africa: A cost-effectiveness analysis , 2017, PLoS medicine.
[14] J. Fortenberry,et al. HIV Continuum of Care for Youth in the United States , 2017, Journal of acquired immune deficiency syndromes.
[15] Paige L. Williams,et al. Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus–Infected Youth , 2017, JAMA pediatrics.
[16] H. Gendelman,et al. Long-acting slow effective release antiretroviral therapy , 2017, Expert opinion on drug delivery.
[17] J. Murray,et al. Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir. , 2016, AIDS research and human retroviruses.
[18] Paige L. Williams,et al. Sexually Transmitted Infections in Youth With Controlled and Uncontrolled Human Immunodeficiency Virus Infection , 2016, Journal of the Pediatric Infectious Diseases Society.
[19] John Brazier,et al. Nothing About Us Without Us? A Comparison of Adolescent and Adult Health-State Values for the Child Health Utility-9D Using Profile Case Best-Worst Scaling. , 2016, Health economics.
[20] M. Bertram,et al. The Case for Adolescent HIV Vaccination in South Africa , 2016, Medicine.
[21] S. Spector,et al. Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age. , 2015, Journal of the Pediatric Infectious Diseases Society.
[22] E. Acosta,et al. Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093 , 2015, The Pediatric infectious disease journal.
[23] J. Brazier,et al. Valuing Child Health Utility 9D Health States with Young Adults: Insights from a Time Trade Off Study , 2015, Applied Health Economics and Health Policy.
[24] Paige L. Williams,et al. Psychiatric symptoms and antiretroviral nonadherence in US youth with perinatal HIV: a longitudinal study , 2015, AIDS.
[25] M. Weinstein,et al. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age , 2015, AIDS.
[26] J. Bauermeister,et al. Rates and Correlates of Antiretroviral Therapy Use and Virologic Suppression Among Perinatally and Behaviorally HIV-Infected Youth Linked to Care in the United States , 2015, Journal of acquired immune deficiency syndromes.
[27] Richard D Moore,et al. The Lifetime Medical Cost Savings From Preventing HIV in the United States , 2015, Medical care.
[28] Joshua T. Cohen,et al. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.
[29] R. Walensky,et al. Individualizing the WHO HIV and infant feeding guidelines: optimal breastfeeding duration to maximize infant HIV-free survival , 2014, AIDS.
[30] Brian C. Zanoni,et al. The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities. , 2014, AIDS patient care and STDs.
[31] S. Spector,et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] C. Delaugerre,et al. French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults , 2014, Journal of the International AIDS Society.
[33] M. Weinstein,et al. Validation and Calibration of a Computer Simulation Model of Pediatric HIV Infection , 2013, PloS one.
[34] M. Weinstein,et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. , 2013, The New England journal of medicine.
[35] J. Caro,et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[36] Jonathan Karnon,et al. Model Parameter Estimation and Uncertainty Analysis , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[37] William Hollingworth,et al. Model Transparency and Validation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[38] Jonathan Karnon,et al. Model Parameter Estimation and Uncertainty: a Report of the Ispor-smdm Modeling Good Research Practices Task Force-6 Background to the Task Forcemodel-parameter-estimation-and- Uncertainty-analysis.asp). a Summary of These Articles Was Pre- Sented at a Plenary Session at the Ispor 16th Annual Intern , 2022 .
[39] J. Sleasman,et al. Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth. , 2012, AIDS patient care and STDs.
[40] R. Walensky,et al. WHO 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe: Modeling Clinical Outcomes in Infants and Mothers , 2011, PloS one.
[41] Matthias Egger,et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis , 2009, AIDS.
[42] S. Reisner,et al. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. , 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[43] John D Seeger,et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] Daniel S. Nagin,et al. Advances in Group-Based Trajectory Modeling and an SAS Procedure for Estimating Them , 2007 .
[45] Milton C Weinstein,et al. Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients , 2006, Journal of acquired immune deficiency syndromes.
[46] J. Lindsey,et al. Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort. , 2006, AIDS research and human retroviruses.
[47] M. Rotheram-Borus,et al. Cost-effectiveness of a behavioral intervention for seropositive youth. , 2005, AIDS education and prevention : official publication of the International Society for AIDS Education.
[48] J. Coast,et al. Quality-Adjusted Life-Years Lack Quality in Pediatric Care: A Critical Review of Published Cost-Utility Studies in Child Health , 2005, Pediatrics.
[49] Milton C Weinstein,et al. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. , 2005, The New England journal of medicine.
[50] Milton C Weinstein,et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. , 2003, The American journal of medicine.
[51] Richard D Moore,et al. Rapid Communication Hospital and Outpatient Health Services Utilization Among HIV‐Infected Patients in Care in 1999 , 2002, Journal of acquired immune deficiency syndromes.
[52] T J Ulahannan,et al. Decision Making in Health and Medicine: Integrating Evidence and Values , 2002 .
[53] S. Kegeles,et al. Cost-effectiveness of the Mpowerment Project, a community-level intervention for young gay men. , 2001 .
[54] M C Weinstein,et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.
[55] K. Roeder,et al. A SAS Procedure Based on Mixture Models for Estimating Developmental Trajectories , 2001 .
[56] David R. Holtgrave,et al. Economic Evaluation of HIV Risk Reduction Intervention in African‐American Male Adolescents , 2000, Journal of acquired immune deficiency syndromes.
[57] P D Cleary,et al. Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. , 2000, The American journal of medicine.
[58] C. Sherbourne,et al. Impact of psychiatric conditions on health-related quality of life in persons with HIV infection. , 2000, The American journal of psychiatry.
[59] M C Weinstein,et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. , 1998, JAMA.
[60] M. Weinstein,et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.
[61] Anne S Frankel,et al. National Institutes of Health , 2019, The Grants Register 2022.
[62] R. Walensky,et al. The Optimal Age for Screening Adolescents and Young Adults Without Identified Risk Factors for HIV. , 2018, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[63] W. Cleveland,et al. Locally Weighted Regression: An Approach to Regression Analysis by Local Fitting , 1988 .
[64] G. Tao,et al. Economic evaluation of an HIV prevention intervention for gay and bisexual male adolescents. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[65] Takuji Nishimura,et al. Mersenne twister: a 623-dimensionally equidistributed uniform pseudo-random number generator , 1998, TOMC.